リポソームドキソルビシン市場、規模、シェア、動向、産業分析レポート：製剤別、製品別、タイプ別、投与経路別、用途別、エンドユーザー別、地域別 - 市場予測、2025年～2034年

Polaris Market Research社の最新調査によると、リポソームドキソルビシンの世界市場規模は2034年までに23億8,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

リポソームドキソルビシン市場は、がん罹患率の増加と効果的な標的治療に対する需要の高まりにより、大きな成長を遂げています。従来のドキソルビシンに比べて副作用が少ないことや、治療効果を高めるデリバリーメカニズムの改善も市場成長の原動力となっています。

適応症の拡大や製剤技術の改良に重点を置いた研究開発が進められており、予測期間中、市場に有利な機会を提供すると期待されます。がん領域におけるリポソーム医薬品の採用拡大や個別化医療の重視といった今後の動向は、今後数年間の市場ダイナミクスを形成すると予想されます。全体として、リポソームドキソルビシン市場は、ドラッグデリバリーシステムとがん治療の進化が続く中、堅調な成長を遂げるものと思われます。

リポソームドキソルビシン市場レポートハイライト

製剤別では、安定性と保存期間の長さから凍結乾燥粉末製剤が市場を独占しています。

製品別では、ブランド認知度の高さと各種がん治療への有効性により、ドキシル製剤が市場をリードしています。リポドックス（Lipodox）セグメントもまた、ドキシルに代わる費用対効果の高い薬剤として人気を集めています。

アントラサイクリン系抗生物質の種類別セグメントは、がん領域での幅広い用途と確立された臨床的有用性により市場をリードしています。

投与経路別では、非経口投与が主流であり、これはがん治療における直接的かつ効果的な投与方法を反映しています。しかし、その潜在的な利便性と有効性から、別の投与経路が検討されています。

用途別では、罹患率の高さと治療法の進歩により、乳がん領域が最大のシェアを占めています。膀胱がんやリンパ腫などの他の分野も成長しているが、そのペースは緩やかです。

リポソームドキソルビシンの主要なエンドユーザーは病院であり、高度な治療プロトコールと患者管理能力がその原動力となっています。専門センターは特定のがん治療に重点を置いているため、採用が増加しています。

北米は、高度なヘルスケア・インフラと革新的な治療法の高い採用率により、支配的な地域となっています。アジア太平洋は、医療投資の増加とがん罹患率の上昇に後押しされ、最も成長率の高い市場です。

同市場の主要企業には、Johnson & Johnson, Lipoxen, Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Hengrui Medicine, Inovio Pharmaceuticals, Aurobindo Pharma, and Profound Medical.などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のリポソームドキソルビシン市場の洞察

• 市場スナップショット
• リポソームドキソルビシン市場力学
  • 促進要因と機会
    • 標的がん治療の採用増加
    • 腫瘍学調査への投資増加
  • 抑制要因と課題
    • リポソームドキソルビシンはあざや出血を引き起こす可能性がある
• PESTEL分析
• リポソームドキソルビシン市場動向
• バリューチェーン分析
• COVID-19の影響分析

第5章 世界のリポソームドキソルビシン市場：製剤別

• 主な調査結果
• イントロダクション
• 凍結乾燥粉末
• ドキソルビシン注射

第6章 世界のリポソームドキソルビシン市場：製品別

• 主な調査結果
• イントロダクション
• ドキシル
• リポドックス
• ミオセット
• その他

第7章 世界のリポソームドキソルビシン市場：タイプ別

• 主な調査結果
• イントロダクション
• アントラサイクリン系抗生物質
• その他

第8章 世界のリポソームドキソルビシン市場：投与経路別

• 主な調査結果
• イントロダクション
• 非経口
• その他

第9章 世界のリポソームドキソルビシン市場：用途別

• 主な調査結果
• イントロダクション
• 膀胱がん
• カポジ肉腫
• 白血病
• リンパ腫
• 乳がん
• その他

第10章 世界のリポソームドキソルビシン市場：エンドユーザー別

• 主な調査結果
• イントロダクション
• 病院
• ホームケア
• 専門センター
• その他

第11章 世界のリポソームドキソルビシン市場：地域別

• 主な調査結果
• イントロダクション
  • リポソームドキソルビシン市場評価：地域、2020～2034年
• 北米
  • 北米：製剤別、2020～2034年
  • 北米：製品別、2020～2034年
  • 北米：タイプ別、2020～2034年
  • 北米：投与経路別、2020～2034年
  • 北米：用途別、2020～2034年
  • 北米：エンドユーザー別、2020～2034年
  • 米国
  • カナダ
• 欧州
  • 欧州：製剤別、2020～2034年
  • 欧州：製品別、2020～2034年
  • 欧州：タイプ別、2020～2034年
  • 欧州：投与経路別、2020～2034年
  • 欧州：用途別、2020～2034年
  • 欧州：エンドユーザー別、2020～2034年
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
  • その他欧州
• アジア太平洋
  • アジア太平洋地域：製剤別、2020～2034年
  • アジア太平洋地域：製品別、2020～2034年
  • アジア太平洋地域：タイプ別、2020～2034年
  • アジア太平洋地域：投与経路別、2020～2034年
  • アジア太平洋地域：用途別、2020～2034年
  • アジア太平洋地域：エンドユーザー別、2020～2034年
  • 中国
  • インド
  • マレーシア
  • 日本
  • インドネシア
  • 韓国
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ
  • 中東・アフリカ：製剤別、2020～2034年
  • 中東・アフリカ：製品別、2020～2034年
  • 中東・アフリカ：タイプ別、2020～2034年
  • 中東・アフリカ：投与経路別、2020～2034年
  • 中東・アフリカ：用途別、2020～2034年
  • 中東・アフリカ：エンドユーザー別、2020～2034年
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東とアフリカ
• ラテンアメリカ
  • ラテンアメリカ：製剤別、2020～2034年
  • ラテンアメリカ：製品別、2020～2034年
  • ラテンアメリカ：タイプ別、2020～2034年
  • ラテンアメリカ：投与経路別、2020～2034年
  • ラテンアメリカ：用途別、2020～2034年
  • ラテンアメリカ：エンドユーザー別、2020～2034年
  • メキシコ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ

第12章 競合情勢

• 拡大と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第13章 企業プロファイル

• Johnson & Johnson
• Lipoxen
• Pfizer
• Mylan
• Teva Pharmaceuticals
• Sun Pharmaceutical Industries
• Hengrui Medicine
• Inovio Pharmaceuticals
• Aurobindo Pharma
• Emcure Pharmaceuticals
• Theradex Pharmaceuticals
• Astellas Pharma

List of Tables:

• Table 1 Global Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 2 Global Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 3 Global Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 4 Global Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 5 Global Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 6 Global Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 7 North America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 8 North America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 9 North America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 10 North America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 11 North America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 12 North America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 13 U.S.: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 14 U.S.: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 15 U.S.: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 16 U.S.: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 17 U.S.: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 18 U.S.: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 19 Canada: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 20 Canada: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 21 Canada: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 22 Canada: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 23 Canada: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 24 Canada: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 25 Europe: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 26 Europe: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 27 Europe: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 28 Europe: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 29 Europe: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 30 Europe: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 31 UK: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 32 UK: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 33 UK: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 34 UK: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 35 UK: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 36 UK: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 37 France: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 38 France: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 39 France: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 40 France: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 41 France: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 42 France: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 43 Germany: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 44 Germany: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 45 Germany: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 46 Germany: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 47 Germany: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 48 Germany: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 49 Italy: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 50 Italy: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 51 Italy: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 52 Italy: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 53 Italy: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 54 Italy: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 55 Spain: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 56 Spain: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 57 Spain: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 58 Spain: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 59 Spain: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 60 Spain: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 61 Netherlands: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 62 Netherlands: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 63 Netherlands: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 64 Netherlands: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 65 Netherlands: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 66 Netherlands: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 67 Russia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 68 Russia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 69 Russia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 70 Russia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 71 Russia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 72 Russia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 73 Rest of Europe: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 74 Rest of Europe: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 75 Rest of Europe: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 76 Rest of Europe: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 77 Rest of Europe: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 78 Rest of Europe: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 79 Asia Pacific: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 80 Asia Pacific: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 81 Asia Pacific: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 82 Asia Pacific: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 83 Asia Pacific: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 84 Asia Pacific: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 85 China: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 86 China: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 87 China: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 88 China: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 89 China: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 90 China: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 91 India: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 92 India: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 93 India: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 94 India: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 95 India: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 96 India: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 97 Malaysia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 98 Malaysia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 99 Malaysia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 100 Malaysia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 101 Malaysia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 102 Malaysia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 103 Japan: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 104 Japan: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 105 Japan: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 106 Japan: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 107 Japan: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 108 Japan: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 109 Indonesia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 110 Indonesia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 111 Indonesia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 112 Indonesia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 113 Indonesia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 114 Indonesia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 115 South Korea: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 116 South Korea: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 117 South Korea: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 118 South Korea: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 119 South Korea: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 120 South Korea: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 121 Australia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 122 Australia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 123 Australia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 124 Australia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 125 Australia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 126 Australia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 127 Rest of Asia Pacific: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 128 Rest of Asia Pacific: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 129 Rest of Asia Pacific: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 130 Rest of Asia Pacific: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 131 Rest of Asia Pacific: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 132 Rest of Asia Pacific: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 133 Middle East & Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 134 Middle East & Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 135 Middle East & Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 136 Middle East & Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 137 Middle East & Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 138 Middle East & Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 139 Saudi Arabia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 140 Saudi Arabia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 141 Saudi Arabia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 142 Saudi Arabia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 143 Saudi Arabia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 144 Saudi Arabia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 145 UAE: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 146 UAE: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 147 UAE: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 148 UAE: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 149 UAE: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 150 UAE: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 151 Israel: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 152 Israel: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 153 Israel: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 154 Israel: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 155 Israel: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 156 Israel: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 157 South Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 158 South Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 159 South Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 160 South Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 161 South Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 162 South Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 163 Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 164 Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 165 Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 166 Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 167 Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 168 Rest of Middle East & Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 169 Latin America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 170 Latin America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 171 Latin America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 172 Latin America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 173 Latin America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 174 Latin America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 175 Mexico: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 176 Mexico: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 177 Mexico: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 178 Mexico: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 179 Mexico: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 180 Mexico: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 181 Brazil: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 182 Brazil: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 183 Brazil: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 184 Brazil: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 185 Brazil: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 186 Brazil: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 187 Argentina: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 188 Argentina: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 189 Argentina: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 190 Argentina: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 191 Argentina: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 192 Argentina: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• Table 193 Rest of Latin America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• Table 194 Rest of Latin America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• Table 195 Rest of Latin America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• Table 196 Rest of Latin America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 197 Rest of Latin America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• Table 198 Rest of Latin America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• List of Figures:
• Figure 1. Global Liposomal Doxorubicin Market, 2020-2034 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Price
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Drug Formulation
• Figure 7. Global Liposomal Doxorubicin Market, by Drug Formulation, 2024 & 2034 (USD Billion)
• Figure 8. Market by Product
• Figure 9. Global Liposomal Doxorubicin Market, by Product, 2024 & 2034 (USD Billion)
• Figure 10. Market by Type
• Figure 11. Global Liposomal Doxorubicin Market, by Type, 2024 & 2034 (USD Billion)
• Figure 12. Market by Route of Administration
• Figure 13. Global Liposomal Doxorubicin Market, by Route of Administration, 2024 & 2034 (USD Billion)
• Figure 14. Market by Application
• Figure 15. Global Liposomal Doxorubicin Market, by Application, 2024 & 2034 (USD Billion)
• Figure 16. Market by End User
• Figure 17. Global Liposomal Doxorubicin Market, by End User, 2024 & 2034 (USD Billion)

The global liposomal doxorubicin market size is expected to reach USD 2.38 billion by 2034, according to a new study by Polaris Market Research. The report "Liposomal Doxorubicin Market Size, Share, Trends, Industry Analysis Report: By Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Product (Doxil, Lipodox, Myocet, and Others), Type (Anthracycline Antibiotic and Others), Route of Administration (Parenteral and Others), Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Others), End User (Hospitals, Homecare, Specialty Centers, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The liposomal doxorubicin market is experiencing significant growth due to increasing cancer prevalence and the rising demand for effective targeted therapies. The drug's ability to reduce side effects compared to conventional doxorubicin and its improved delivery mechanism that enhances therapeutic efficacy also drive the market growth.

Ongoing research and development, which focuses on expanding indications and improving formulation technologies, is expected to offer lucrative opportunities for the market during the forecast period. Future trends, such as the growing adoption of liposomal drugs in oncology and the emphasis on personalized medicines, are expected to shape the market dynamics in the coming years. Overall, the liposomal doxorubicin market is poised for robust growth as advancements in drug delivery systems and cancer treatment continue to evolve.

Liposomal Doxorubicin Market Report Highlights:

By drug formulation, the lyophilized powder segment dominates the market due to its stability and longer shelf life.

In terms of product, the Doxil segment leads this market, driven by its strong brand recognition and effectiveness in treating various cancers. The Lipodox segment is also gaining traction as a cost-effective alternative to Doxil.

The anthracycline antibiotic segment, by type, leads the market due to its broad application in oncology and established clinical benefits.

By route of administration, the parenteral route is the dominant method, reflecting its direct and effective delivery in cancer treatment. However, alternative routes are being explored for their potential convenience and efficacy.

Based on application, the breast cancer segment holds the largest share due to its high incidence rate and ongoing advancements in treatment options. Other segments, such as bladder cancer and lymphoma, are also growing but at a slower pace.

Hospitals are the primary end users of liposomal doxorubicin, driven by their capacity for advanced treatment protocols and patient management. Specialty Centers are showing increasing adoption due to their focus on specific cancer treatments.

North America is the dominant region due to advanced healthcare infrastructure and high adoption rates of innovative therapies. Asia Pacific is the highest-growing market, propelled by increasing healthcare investments and rising cancer prevalence.

Some of the key companies in the market are Johnson & Johnson, Lipoxen, Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Hengrui Medicine, Inovio Pharmaceuticals, Aurobindo Pharma, and Profound Medical.

Polaris Market Research has segmented the liposomal doxorubicin market report on the basis of drug formulation, product, type, route of administration, application, end user, and region:

By Drug Formulation Outlook (Revenue - USD Billion, 2020-2034)

• Lyophilized Powder
• Doxorubicin Injection

By Product Outlook (Revenue - USD Billion, 2020-2034)

• Doxil
• Lipodox
• Myocet
• Others

By Type Outlook (Revenue - USD Billion, 2020-2034)

• Anthracycline Antibiotic
• Others

By Route of Administration Outlook (Revenue - USD Billion, 2020-2034)

• Parenteral
• Others

By Application Outlook (Revenue - USD Billion, 2020-2034)

• Bladder Cancer
• Kaposi Sarcoma
• Leukemia
• Lymphoma
• Breast Cancer
• Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

• Hospitals
• Homecare
• Specialty Centers
• Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa
• Latin America
• Mexico
• Brazil
• Argentina
• Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Liposomal Doxorubicin Market Insights

• 4.1. Liposomal Doxorubicin Market - Market Snapshot
• 4.2. Liposomal Doxorubicin Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Adoption of Targeted Cancer Therapies
    • 4.2.1.2. Rising Investments in Oncology Research
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Liposomal doxorubicin may cause bruising and bleeding
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Liposomal Doxorubicin Market Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Liposomal Doxorubicin Market, by Drug Formulation

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
• 5.3. Lyophilized Powder
  • 5.3.1. Global Liposomal Doxorubicin Market, by Lyophilized Powder, by Region, 2020-2034 (USD Billion)
• 5.4. Doxorubicin Injection
  • 5.4.1.1. Global Liposomal Doxorubicin Market, by Doxorubicin Injection, by Region, 2020-2034 (USD Billion)

6. Global Liposomal Doxorubicin Market, by Product

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
• 6.3. Doxil
  • 6.3.1. Global Liposomal Doxorubicin Market, by Doxil, by Region, 2020-2034 (USD Billion)
• 6.4. Lipodox
  • 6.4.1. Global Liposomal Doxorubicin Market, by Lipodox, by Region, 2020-2034 (USD Billion)
• 6.5. Myocet
  • 6.5.1. Global Liposomal Doxorubicin Market, by Myocet, by Region, 2020-2034 (USD Billion)
• 6.6. Others
  • 6.6.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Liposomal Doxorubicin Market, by Type

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
• 7.3. Anthracycline Antibiotic
  • 7.3.1. Global Liposomal Doxorubicin Market, by Anthracycline Antibiotic, by Region, 2020-2034 (USD Billion)
• 7.4. Others
  • 7.4.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Liposomal Doxorubicin Market, by Route of Administration

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
• 8.3. Parenteral
  • 8.3.1. Global Liposomal Doxorubicin Market, by Parenteral, by Region, 2020-2034 (USD Billion)
• 8.4. Others
  • 8.4.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Liposomal Doxorubicin Market, by Application

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Global Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
• 9.3. Bladder Cancer
  • 9.3.1. Global Liposomal Doxorubicin Market, by Bladder Cancer, by Region, 2020-2034 (USD Billion)
• 9.4. Kaposi Sarcoma
  • 9.4.1. Global Liposomal Doxorubicin Market, Kaposi Sarcoma, by Region, 2020-2034 (USD Billion)
• 9.5. Leukemia
  • 9.5.1. Global Liposomal Doxorubicin Market, by Leukemia, by Region, 2020-2034 (USD Billion)
• 9.6. Lymphoma
  • 9.6.1. Global Liposomal Doxorubicin Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
• 9.7. Breast Cancer
  • 9.7.1. Global Liposomal Doxorubicin Market, by Breast Cancer, by Region, 2020-2034 (USD Billion)
• 9.8. Others
  • 9.8.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

10. Global Liposomal Doxorubicin Market, by End User

• 10.1. Key Findings
• 10.2. Introduction
  • 10.2.1. Global Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• 10.3. Hospitals
  • 10.3.1. Global Liposomal Doxorubicin Market, by Hospitals, by Region, 2020-2034 (USD Billion)
• 10.4. Homecare
  • 10.4.1. Global Liposomal Doxorubicin Market, by Homecare, by Region, 2020-2034 (USD Billion)
• 10.5. Specialty Centers
  • 10.5.1. Global Liposomal Doxorubicin Market, Specialty Centers, by Region, 2020-2034 (USD Billion)
• 10.6. Others
  • 10.6.1. Global Liposomal Doxorubicin Market, by Others, by Region, 2020-2034 (USD Billion)

11. Global Liposomal Doxorubicin Market, by Geography

• 11.1. Key Findings
• 11.2. Introduction
  • 11.2.1. Liposomal Doxorubicin Market Assessment, By Geography, 2020-2034 (USD Billion)
• 11.3. Liposomal Doxorubicin Market - North America
  • 11.3.1. North America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
  • 11.3.2. North America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
  • 11.3.3. North America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
  • 11.3.4. North America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
  • 11.3.5. North America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
  • 11.3.6. North America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.3.7. Liposomal Doxorubicin Market - U.S.
    • 11.3.7.1. U.S.: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.3.7.2. U.S.: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.3.7.3. U.S.: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.3.7.4. U.S.: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.3.7.5. U.S.: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.3.7.6. U.S.: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.3.8. Liposomal Doxorubicin Market - Canada
    • 11.3.8.1. Canada: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.3.8.2. Canada: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.3.8.3. Canada: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.3.8.4. Canada: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.3.8.5. Canada: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.3.8.6. Canada: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• 11.4. Liposomal Doxorubicin Market - Europe
  • 11.4.1. Europe: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
  • 11.4.2. Europe: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
  • 11.4.3. Europe: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
  • 11.4.4. Europe: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
  • 11.4.5. Europe: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
  • 11.4.6. Europe: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.7. Liposomal Doxorubicin Market - UK
    • 11.4.7.1. UK: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.7.2. UK: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.7.3. UK: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.7.4. UK: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.7.5. UK: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.7.6. UK: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.8. Liposomal Doxorubicin Market - France
    • 11.4.8.1. France: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.8.2. France: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.8.3. France: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.8.4. France: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.8.5. France: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.8.6. France: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.9. Liposomal Doxorubicin Market - Germany
    • 11.4.9.1. Germany: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.9.2. Germany: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.9.3. Germany: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.9.4. Germany: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.9.5. Germany: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.9.6. Germany: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.10. Liposomal Doxorubicin Market - Italy
    • 11.4.10.1. Italy: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.10.2. Italy: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.10.3. Italy: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.10.4. Italy: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.10.5. Italy: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.10.6. Italy: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.11. Liposomal Doxorubicin Market - Spain
    • 11.4.11.1. Spain: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.11.2. Spain: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.11.3. Spain: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.11.4. Spain: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.11.5. Spain: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.11.6. Spain: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.12. Liposomal Doxorubicin Market - Netherlands
    • 11.4.12.1. Netherlands: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.12.2. Netherlands: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.12.3. Netherlands: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.12.4. Netherlands: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.12.5. Netherlands: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.12.6. Netherlands: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.13. Liposomal Doxorubicin Market - Russia
    • 11.4.13.1. Russia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.13.2. Russia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.13.3. Russia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.13.4. Russia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.13.5. Russia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.13.6. Russia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.4.14. Liposomal Doxorubicin Market - Rest of Europe
    • 11.4.14.1. Rest of Europe: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.4.14.2. Rest of Europe: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.4.14.3. Rest of Europe: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.4.14.4. Rest of Europe: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.4.14.5. Rest of Europe: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.4.14.6. Rest of Europe: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• 11.5. Liposomal Doxorubicin Market - Asia Pacific
  • 11.5.1. Asia Pacific: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
  • 11.5.2. Asia Pacific: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
  • 11.5.3. Asia Pacific: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
  • 11.5.4. Asia Pacific: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
  • 11.5.5. Asia Pacific: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
  • 11.5.6. Asia Pacific: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.7. Liposomal Doxorubicin Market - China
    • 11.5.7.1. China: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.7.2. China: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.7.3. China: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.7.4. China: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.7.5. China: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.7.6. China: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.8. Liposomal Doxorubicin Market - India
    • 11.5.8.1. India: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.8.2. India: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.8.3. India: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.8.4. India: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.8.5. India: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.8.6. India: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.9. Liposomal Doxorubicin Market - Malaysia
    • 11.5.9.1. Malaysia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.9.2. Malaysia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.9.3. Malaysia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.9.4. Malaysia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.9.5. Malaysia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.9.6. Malaysia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.10. Liposomal Doxorubicin Market - Japan
    • 11.5.10.1. Japan: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.10.2. Japan: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.10.3. Japan: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.10.4. Japan: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.10.5. Japan: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.10.6. Japan: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.11. Liposomal Doxorubicin Market - Indonesia
    • 11.5.11.1. Indonesia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.11.2. Indonesia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.11.3. Indonesia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.11.4. Indonesia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.11.5. Indonesia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.11.6. Indonesia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.12. Liposomal Doxorubicin Market - South Korea
    • 11.5.12.1. South Korea: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.12.2. South Korea: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.12.3. South Korea: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.12.4. South Korea: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.12.5. South Korea: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.12.6. South Korea: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.13. Liposomal Doxorubicin Market - Australia
    • 11.5.13.1. Australia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.13.2. Australia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.13.3. Australia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.13.4. Australia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.13.5. Australia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.13.6. Australia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.5.14. Liposomal Doxorubicin Market - Rest of Asia Pacific
    • 11.5.14.1. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.5.14.2. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.5.14.3. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.5.14.4. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.5.14.5. Rest of Asia Pacific: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.5.14.6. Rest of Asia Pacific: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• 11.6. Liposomal Doxorubicin Market - Middle East & Africa
  • 11.6.1. Middle East & Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
  • 11.6.2. Middle East & Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
  • 11.6.3. Middle East & Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
  • 11.6.4. Middle East & Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
  • 11.6.5. Middle East & Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
  • 11.6.6. Middle East & Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.6.7. Liposomal Doxorubicin Market - Saudi Arabia
    • 11.6.7.1. Saudi Arabia: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.6.7.2. Saudi Arabia: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.6.7.3. Saudi Arabia: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.6.7.4. Saudi Arabia: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.6.7.5. Saudi Arabia: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.6.7.6. Saudi Arabia: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.6.8. Liposomal Doxorubicin Market - UAE
    • 11.6.8.1. UAE: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.6.8.2. UAE: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.6.8.3. UAE: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.6.8.4. UAE: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.6.8.5. UAE: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.6.8.6. UAE: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.6.9. Liposomal Doxorubicin Market - Israel
    • 11.6.9.1. Israel: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.6.9.2. Israel: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.6.9.3. Israel: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.6.9.4. Israel: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.6.9.5. Israel: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.6.9.6. Israel: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.6.10. Liposomal Doxorubicin Market - South Africa
    • 11.6.10.1. South Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.6.10.2. South Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.6.10.3. South Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.6.10.4. South Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.6.10.5. South Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.6.10.6. South Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.6.11. Liposomal Doxorubicin Market - Rest of Middle East & Africa
    • 11.6.11.1. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.6.11.2. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.6.11.3. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.6.11.4. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.6.11.5. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.6.11.6. Rest of Middle East & Africa: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
• 11.7. Liposomal Doxorubicin Market - Latin America
  • 11.7.1. Latin America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
  • 11.7.2. Latin America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
  • 11.7.3. Latin America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
  • 11.7.4. Latin America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
  • 11.7.5. Latin America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
  • 11.7.6. Latin America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.7.7. Liposomal Doxorubicin Market - Mexico
    • 11.7.7.1. Mexico: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.7.7.2. Mexico: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.7.7.3. Mexico: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.7.7.4. Mexico: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.7.7.5. Mexico: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.7.7.6. Mexico: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.7.8. Liposomal Doxorubicin Market - Brazil
    • 11.7.8.1. Brazil: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.7.8.2. Brazil: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.7.8.3. Brazil: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.7.8.4. Brazil: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.7.8.5. Brazil: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.7.8.6. Brazil: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.7.9. Liposomal Doxorubicin Market - Argentina
    • 11.7.9.1. Argentina: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.7.9.2. Argentina: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.7.9.3. Argentina: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.7.9.4. Argentina: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.7.9.5. Argentina: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.7.9.6. Argentina: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)
  • 11.7.10. Liposomal Doxorubicin Market - Rest of Latin America
    • 11.7.10.1. Rest of Latin America: Liposomal Doxorubicin Market, by Drug Formulation, 2020-2034 (USD Billion)
    • 11.7.10.2. Rest of Latin America: Liposomal Doxorubicin Market, by Product, 2020-2034 (USD Billion)
    • 11.7.10.3. Rest of Latin America: Liposomal Doxorubicin Market, by Type, 2020-2034 (USD Billion)
    • 11.7.10.4. Rest of Latin America: Liposomal Doxorubicin Market, by Route of Administration, 2020-2034 (USD Billion)
    • 11.7.10.5. Rest of Latin America: Liposomal Doxorubicin Market, by Application, 2020-2034 (USD Billion)
    • 11.7.10.6. Rest of Latin America: Liposomal Doxorubicin Market, by End User, 2020-2034 (USD Billion)

12. Competitive Landscape

• 12.1. Expansion and Acquisition Analysis
  • 12.1.1. Expansion
  • 12.1.2. Acquisitions
• 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

• 13.1. Johnson & Johnson
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Benchmarking
  • 13.1.4. Recent Development
• 13.2. Lipoxen
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Benchmarking
  • 13.2.4. Recent Development
• 13.3. Pfizer
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Benchmarking
  • 13.3.4. Recent Development
• 13.4. Mylan
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Benchmarking
  • 13.4.4. Recent Development
• 13.5. Teva Pharmaceuticals
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Benchmarking
  • 13.5.4. Recent Development
• 13.6. Sun Pharmaceutical Industries
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Benchmarking
  • 13.6.4. Recent Development
• 13.7. Hengrui Medicine
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Benchmarking
  • 13.7.4. Recent Development
• 13.8. Inovio Pharmaceuticals
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Benchmarking
  • 13.8.4. Recent Development
• 13.9. Aurobindo Pharma
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Benchmarking
  • 13.9.4. Recent Development
• 13.10. Emcure Pharmaceuticals
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Benchmarking
  • 13.10.4. Recent Development
• 13.11. Theradex Pharmaceuticals
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Benchmarking
  • 13.11.4. Recent Development
• 13.12. Astellas Pharma
  • 13.12.1. Company Overview
  • 13.12.2. Financial Performance
  • 13.12.3. Product Benchmarking
  • 13.12.4. Recent Development